» Articles » PMID: 39133676

Extracellular Domain, Hinge, and Transmembrane Determinants Affecting Surface CD4 Expression of a Novel Anti-HIV Chimeric Antigen Receptor (CAR) Construct

Overview
Journal PLoS One
Date 2024 Aug 12
PMID 39133676
Authors
Affiliations
Soon will be listed here.
Abstract

Chimeric antigen receptor (CAR)-T cells have demonstrated clinical potential, but current receptors still need improvements to be successful against chronic HIV infection. In this study, we address some requirements of CAR motifs for strong surface expression of a novel anti-HIV CAR by evaluating important elements in the extracellular, hinge, and transmembrane (TM) domains. When combining a truncated CD4 extracellular domain and CD8α hinge/TM, the novel CAR did not express extracellularly but was detectable intracellularly. By shortening the CD8α hinge, CD4-CAR surface expression was partially recovered and addition of the LYC motif at the end of the CD8α TM fully recovered both intracellular and extracellular CAR expression. Mutation of LYC to TTA or TTC showed severe abrogation of CAR expression by flow cytometry and confocal microscopy. Additionally, we determined that CD4-CAR surface expression could be maximized by the removal of FQKAS motif at the junction of the extracellular domain and the hinge region. CD4-CAR surface expression also resulted in cytotoxic CAR T cell killing of HIV Env+ target cells. In this study, we identified elements that are crucial for optimal CAR surface expression, highlighting the need for structural analysis studies to establish fundamental guidelines of CAR designs.

References
1.
Sahu G, Sango K, Selliah N, Ma Q, Skowron G, Junghans R . Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology. 2013; 446(1-2):268-75. PMC: 3791854. DOI: 10.1016/j.virol.2013.08.002. View

2.
Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K . Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012; 4(132):132ra53. PMC: 4368443. DOI: 10.1126/scitranslmed.3003761. View

3.
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C . Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci. 2019; 15(12):2548-2560. PMC: 6854376. DOI: 10.7150/ijbs.34213. View

4.
Cerutti N, Killick M, Jugnarain V, Papathanasopoulos M, Capovilla A . Disulfide reduction in CD4 domain 1 or 2 is essential for interaction with HIV glycoprotein 120 (gp120), which impairs thioredoxin-driven CD4 dimerization. J Biol Chem. 2014; 289(15):10455-10465. PMC: 4036167. DOI: 10.1074/jbc.M113.539353. View

5.
Benmebarek M, Karches C, Cadilha B, Lesch S, Endres S, Kobold S . Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019; 20(6). PMC: 6470706. DOI: 10.3390/ijms20061283. View